J 2011

Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen

SZTURZ, Petr, Zdeněk ADAM, Mária KLINCOVÁ, Josef FEIT, Marta KREJČÍ et. al.

Basic information

Original name

Multiple Myeloma Associated IgA Pemphigus: Treatment With Bortezomib- and Lenalidomide-Based Regimen

Authors

SZTURZ, Petr (203 Czech Republic, guarantor, belonging to the institution), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Mária KLINCOVÁ (703 Slovakia, belonging to the institution), Josef FEIT (203 Czech Republic, belonging to the institution), Marta KREJČÍ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), Lenka ZAHRADOVÁ (203 Czech Republic, belonging to the institution), Vladimír VAŠKŮ (203 Czech Republic, belonging to the institution), Roman HÁJEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Clinical Lymphoma, Myeloma & Leukemia, 2011, 2152-2650

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.880

RIV identification code

RIV/00216224:14110/11:00054365

Organization unit

Faculty of Medicine

UT WoS

000298280200010

Keywords in English

Autoimmunity; Bortezomib; IgA pemphigus; Lenalidomide; Multiple myeloma; Paraproteinemia

Tags

International impact
Změněno: 12/10/2012 19:11, doc. MUDr. Petr Szturz, Ph.D.

Abstract

V originále

Generally, monoclonal immunoglobulins do not bind an autologous antigen, except for some cases, when it causes immune damage to body’s own tissues. Vesiculopustulous dermatitis associated with immunoglobulin (Ig) A deposition in the epidermis represents an autoimmune skin manifestation of monoclonal gammopathy. It is commonly referred to as subcorneal pustular dermatosis type of IgA pemphigus.1 In our previous work, we reported on complete and long-term remission of multiple myeloma associated IgA pemphigus after treatment with a bortezomib (Velcade) based regimen.2 In this work, to our knowledge, we are the first to publish a convincing clinical remission and excellent drug tolerance of a subsequent lenalidomide (Revlimid) based regimen used in the same patient for management of the relapsed disease.

Links

LC06027, research and development project
Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)
Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NT11154, research and development project
Name: Úloha mitotické disrupce v B lymfocytech u mnohočetném myelomu
Investor: Ministry of Health of the CR